Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group–American College of Radiology Imaging Network E4512): a phase 3 trial

Study limitation reported by the research below: “The brand name 'Xalkori' for crizotinib was inferred from standard drug databases; not explicitly stated in the abstract.”